Piotr Sawrycki
Provincial Polyclinical Hospital in Toruń(PL)
Publications by Year
Research Areas
Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Renal and related cancers
Most-Cited Works
- → Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma(2021)723 cited
- → Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial(2022)267 cited
- → Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma(2024)255 cited
- → Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial(2019)162 cited
- → Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer(2018)90 cited
- → Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.(2021)38 cited
- → Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).(2024)35 cited
- → Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer(2013)34 cited
- → Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.(2022)30 cited
- → Chemotherapy control by breath profile with application of SPME‐GC/MS method(2012)29 cited